|Bid||0.3000 x 2200|
|Ask||0.8000 x 3100|
|Day's Range||0.4800 - 0.5000|
|52 Week Range||0.3500 - 2.6500|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biopharmaceutical company Sorrento Therapeutics Inc. has filed lawsuits against Dr. Patrick Soon-Shiong and his NantWorks network of companies, accusing the biotech entrepreneur of engaging in a “catch and kill” plan that ultimately blocked the release of Sorrento’s new cancer drug.
NantCell, a cancer treatment company founded by biotech entrepreneur Dr. Patrick Soon-Shiong, has received an additional $30 million investment from drug maker Celgene Corp.